Custom In Vivo Tumor Model Services

Online Inquiry

Name *

Email *

Phone *

Services Interested *

Project Description

Please note that we are not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.

NCI-N87 Trastuzumab-Resistant HER2+ Gastric Cancer Model Service

Fig 1: NCI-N87 Trastuzumab-Resistant HER2+ Gastric Cancer Model preclinical research.

The NCI-N87 Trastuzumab-Resistant HER2+ Gastric Cancer Model Service supplies a rigorously validated in vitro and in vivo system for dissecting acquired resistance to trastuzumab in HER2-positive gastric cancer. Alfa Cytology supports this service across its full preclinical lifecycle—continuous trastuzumab exposure and resistant subline establishment, resistance-index confirmation at cellular and whole-tumor levels, and mechanism-oriented endpoint analysis—enabling clients to advance anti-HER2 combination and reversal programs with confidence.

Overview of NCI-N87 Trastuzumab-Resistant HER2+ Gastric Cancer Model

The NCI-N87 trastuzumab-resistant HER2+ gastric cancer model is derived from NCI-N87, a well-characterized human gastric carcinoma cell line with high-level HER2 amplification, which is rendered resistant to trastuzumab through prolonged, escalating exposure to the antibody. The resulting resistant variant—frequently designated NCI-N87/TR—continues to express HER2 but no longer responds to trastuzumab-mediated growth inhibition, faithfully reproducing the acquired resistance that limits long-term anti-HER2 therapy in gastric cancer. Because NCI-N87 harbors a known genomic background with consistent HER2 dependency, its resistant derivative offers a clean, interpretable background against which resistance drivers can be identified and targeted.

Fig 2: Reference figures for NCI-N87 Trastuzumab-Resistant HER2+ Gastric Cancer Model. Fig 1. Full resistance mechanism map of the NCI-N87 trastuzumab-resistant model: NRG1-HER4-YAP1, HER2-SHCBP1-PLK1, PLOD3-FOXO3-survivin, PIK3CA/KLK10/XB130/MACC1→PI3K-AKT-mTOR-RPS6-NRF2, FGFR3/IGF-1R/miR-301a-3p bypass, SRC/STAT3, MUC1/IQGAP1/GSE1-BCL2, miR-21-PTEN, miR-233-FBXW7, Wnt/β-catenin, IL-6/Notch and CCL2-ZC3H12A-TRAF6/3 axes. (Li, Zhifei, et al., 2024)

Resistance in this model is multifactorial rather than a single-gene event. Documented mechanisms in trastuzumab-resistant gastric cancer sublines derived from NCI-N87 include compensatory activation of the PI3K/AKT/mTOR axis through loss of PTEN or activation of IGF-1R, up-regulation of alternative receptor tyrosine kinases such as FGFR3, metabolic rewiring toward aerobic glycolysis, and altered apoptotic thresholds that blunt trastuzumab-induced cell death. At the whole-tumor level, resistant NCI-N87 xenografts in immunodeficient mice grow robustly despite trastuzumab treatment, providing a physiologic setting in which antibody efficacy, combination regimens, and candidate resistance-reversal agents can be benchmarked side by side with the sensitive parental model.

Principles of NCI-N87 Trastuzumab-Resistant HER2+ Gastric Cancer Model Construction

Model construction is grounded in chronic selective pressure with a large-molecule agent. Unlike small-molecule selection, trastuzumab cannot simply be left in the medium at a fixed high concentration: antibody activity depends on serum quality, target engagement, and regular medium renewal, so resistance is built through repeated, progressively intensified exposure cycles interleaved with recovery phases. Rare cells that up-regulate bypass signaling or anti-apoptotic programs survive each cycle and gradually take over the culture, and the resulting population is locked into a stable resistant phenotype that persists after antibody withdrawal.

Principle / Parameter	Detailed Description
Selection agent	Trastuzumab, a humanized anti-HER2 IgG1 monoclonal antibody, applied directly to cultured NCI-N87 cells; serum-containing complete medium is required to preserve antibody activity during exposure cycles.
Exposure regimen	Chronic intermittent exposure starting at a low, sub-inhibitory concentration (e.g., 1–5 µg/mL) with medium refreshed every 2–3 days during each cycle; the concentration is escalated stepwise over months of continuous selection until a maintenance level (commonly around 10 µg/mL or higher) is tolerated.
Cycle design	Each selection cycle combines an exposure window with a drug-free recovery window, allowing surviving cells to repopulate; this pulse–recovery pattern enriches heritable resistance mechanisms while limiting non-specific stress adaptation.
Phenotype stabilization	After target-level resistance is reached, the subline is maintained for extended passages under selection, then rested in antibody-free medium to confirm that reduced sensitivity is stable and not residual antibody carryover.
Core resistance mechanisms	Compensatory PI3K/AKT/mTOR pathway activation (PTEN loss, IGF-1R hyperphosphorylation), up-regulation of bypass receptor tyrosine kinases (e.g., FGFR3, IGF-1R), metabolic reprogramming (Warburg effect, glycolytic enzyme activation), and altered apoptotic signaling collectively blunt trastuzumab action.
Resistance quantification	Sensitivity is quantified by comparing IC₅₀/growth-inhibition curves of parental and resistant cells under trastuzumab (MTT, CCK-8, or real-time impedance assays); colony-formation assays provide a longer-term readout of clonogenic survival.
Phenotype validation	Validation panels typically include HER2 expression and phosphorylation status, downstream p-AKT/p-mTOR signaling, cell-cycle and apoptosis analysis, and sphere-formation or anchorage-independent growth assays to capture aggressive subpopulations.
In vivo extension	Resistant NCI-N87 cells (often 5 × 10⁶ cells per site, frequently combined 1:1 with Matrigel) are implanted subcutaneously into immunodeficient mice and passaged under trastuzumab to generate a stable resistant xenograft line mirroring clinical acquired resistance.

Our Services

With hands-on experience in chronic antibody selection and resistant xenograft management, Alfa Cytology provides the NCI-N87 trastuzumab-resistant HER2+ gastric cancer model as a dependable preclinical workhorse: from the first low-dose exposure cycle to fully documented resistant cell banks and matching xenograft cohorts, each deliverable is accompanied by traceable characterization data designed to slot directly into mechanism and combination-efficacy studies.

Workflow of NCI-N87 Trastuzumab-Resistant HER2+ Gastric Cancer Model Construction

Construction proceeds as a monitored, multi-month program rather than a single manipulation, because antibody resistance emerges gradually and must be distinguished from transient stress responses. Parental baseline characterization is captured first, selection intensity is increased only after stable regrowth is confirmed, and every milestone is backed by quantitative sensitivity testing. The typical sequence is as follows:

Parental line authentication and baseline testing: NCI-N87 cells are revived, mycoplasma-tested and authenticated, and their HER2 expression and trastuzumab sensitivity (IC₅₀, maximal inhibition) are recorded as the reference baseline.
Initiation of chronic trastuzumab exposure: Early-passage cells are seeded and exposed to a low trastuzumab concentration (about 1–5 µg/mL) in complete medium, which is replenished every 2–3 days to keep antibody activity consistent.
Escalation under pulse–recovery cycles: After each round of regrowth, the trastuzumab concentration is raised incrementally (commonly by 1–2 µg/mL per cycle) over several months until cells proliferate robustly at a high maintenance concentration (around 10 µg/mL or above).
Stabilization and drug-free rest: The resistant pool is passaged continuously under selection, then cultured without antibody for approximately two weeks to verify that reduced sensitivity is heritable rather than carryover-dependent.
In vitro resistance confirmation. Dose–response assays (MTT/CCK-8 or impedance-based growth curves) and colony-formation assays compare parental and resistant cells, and the resistance phenotype is expressed as a fold-change in IC₅₀ or surviving fraction.
Molecular characterization: HER2 total and phosphorylated protein, downstream p-AKT/p-mTOR signaling, candidate bypass kinases (IGF-1R, FGFR3), apoptosis markers, and cell-cycle profiles are examined to map the resistance mechanism landscape.
Resistant xenograft establishment (optional: in vivo stage). Validated resistant cells (typically 5 × 10⁶ per mouse, often 1:1 with Matrigel) are inoculated subcutaneously into immunodeficient mice, and tumors are passaged in vivo under trastuzumab to consolidate the resistant phenotype at the whole-tumor level.
Final quality control and release: A release package is compiled covering authentication, mycoplasma status, passage history, resistance-index reports, molecular readouts, and xenograft growth documentation, after which the model is handed over for study use.

Fig 3: Workflow for the establishment of NCI-N87 Trastuzumab-Resistant HER2+ Gastric Cancer Models. Fig 2. NCI-N87 Trastuzumab-Resistant HER2+ Gastric Cancer Model Construction Workflow.

Case Study-NCI-N87 Trastuzumab-Resistant HER2+ Gastric Cancer Model Development

In a recent preclinical program, the Alfa Cytology team generated and characterized a trastuzumab-resistant NCI-N87 subline for a client evaluating next-generation anti-HER2 combination strategies. Chronic stepwise exposure produced a stable resistant population with markedly reduced trastuzumab sensitivity relative to the parental line, and molecular profiling pointed to compensatory activation of survival signaling as a dominant resistance layer. The validated subline was subsequently applied to combination-treatment screening, and parallel resistant xenograft cohorts were established to confirm key findings in an in vivo context. Program-specific datasets and study reports from this and comparable engagements are available upon request under confidentiality.

Fig 4: Case Study-NCI-N87 Trastuzumab-Resistant HER2+ Gastric Cancer Model Development.

Why Choose Alfa Cytology?

Alfa Cytology pairs disciplined, months-long selection expertise with transparent quality control, so each NCI-N87 trastuzumab-resistant model is delivered with the evidence researchers need to trust their resistance data. Specific advantages of working with us include:

Proven chronic-exposure methodology that yields stable, heritable trastuzumab resistance rather than transient adaptation.
Quantitative resistance confirmation using matched parental controls and multiple orthogonal assay formats.
Mechanism-focused characterization spanning HER2 signaling, bypass kinase activation, and apoptosis readouts.
Integrated in vitro and in vivo offerings with resistant xenografts consolidated under antibody pressure.
Complete traceability through authentication, mycoplasma screening, passage logs, and milestone-based reporting.
Responsive, confidential project management with deliverables formatted for direct use in downstream studies.

Contact Us

Ready to advance your anti-HER2 research with a validated resistance model? Reach out to us to explore how the NCI-N87 trastuzumab-resistant HER2+ gastric cancer model can support your preclinical program. Contact the Alfa Cytology team today for a tailored study design, schedule, and quote.

Reference

Li, Zhifei, et al. "Mechanisms of resistance to trastuzumab in HER2-positive gastric cancer." Chinese Journal of Cancer Research 36.3 (2024): 306.

For research use only. Not intended for any clinical use.